SLC3A2 and Miyoshi myopathy: These data demonstrate that oncogenic RAS and SLC3A2 are required for amino acid-dependent mTORC1 signaling in MM, consistent with a model where RAS commandeers mTORC1 signaling by orchestrating components of the amino acid sensing machinery.